Bristol-Myers Squibb Opdualag — Total Revenues increased by 5.3% to $299.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 28.3%, from $233.00M to $299.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates strong market adoption and successful clinical positioning of the drug, while a decrease may signal increased competition or loss of market share in the immuno-oncology space.
This metric represents the total global net sales generated from the commercialization of Opdualag, a fixed-dose combina...
Comparable to revenue metrics for specific high-growth specialty pharmaceutical products or blockbusters in the oncology portfolios of peer biopharmaceutical companies.
bmy_segment_opdualag_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $6.00M | $58.00M | $84.00M | $104.00M | $117.00M | $154.00M | $166.00M | $190.00M | $206.00M | $235.00M | $233.00M | $254.00M | $252.00M | $284.00M | $299.00M |
| QoQ Change | — | — | — | — | +866.7% | +44.8% | +23.8% | +12.5% | +31.6% | +7.8% | +14.5% | +8.4% | +14.1% | -0.9% | +9.0% | -0.8% | +12.7% | +5.3% |
| YoY Change | — | — | — | — | — | — | — | >999% | +165.5% | +97.6% | +82.7% | +76.1% | +52.6% | +40.4% | +33.7% | +22.3% | +20.9% | +28.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.